Sacituzumab govitecan (anti-TROP2) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan (anti-TROP2) shows anticancer activity.
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Sacituzumab govitecan (anti-TROP2) (Ab175650) - Flow Cytometry Flow Cytometry analysis of MCF7 cells labelling TROP2 (red) with Sacituzumab govitecan (anti-TROP2) (Ab175650) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Sacituzumab govitecan (anti-TROP2) (Ab175650) - SEC The purity of Sacituzumab govitecan (anti-TROP2) (Ab175650) is more than 95% verified by HPLC.
Sacituzumab govitecan (anti-TROP2) (Ab175650) - ELISA Immobilized Recombinant huTROP2 (ECD)-chis protein at 2.0 μg/mL can bind Sacituzumab govitecan (anti-TROP2) (Ab175650) with the EC₅₀ of 5.81 ng/mL.